RxDoctor Payments DataLook up a doctor →

Richard Bennett, MD

Urology · Royal Oak, MINPI 1932313574

Payments from drug & device makers

$368,245in general payments, 2019–2025

Across 703 payments — averaging $523.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Endo Pharmaceuticals Inc.$331K
  • Endo USA, Inc.$30K
  • Axonics, Inc.$2K
  • Boston Scientific$972
  • Johnson & Johnson$596
  • Antares Pharma, Inc.$440
  • plus $4K from 51 others

What the payments were for

  • Consulting fees$50,36514%
  • Speaking & faculty fees$241,52567%
  • Travel & lodging$55,16915%
  • Food & beverage$13,7424%
  • Education$4190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$368,245 in reported general payments places this provider in the 95th percentile of 400 urology providers in Michigan.

See all urology providers in Michigan

Medicare billing

Part B allowed, 2024
$76,701
Medicare patients
289
Services billed
736

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron136$92,271
GemtesaVibegron120$78,291
XyostedTestosterone Enanthate92$70,616
OrgovyxRelugolix18$46,359
Mirabegron ErMirabegron62$32,805
Tamsulosin Hcl645$13,354
Trospium Chloride ErTrospium Chloride31$6,225
Testosterone37$4,881
Potassium Citrate ErPotassium Citrate45$4,252
Alfuzosin Hcl ErAlfuzosin Hcl96$3,734
Tadalafil62$3,298
Testosterone Cypionate42$2,640
Testosterone Enanthate42$2,639
Cabergoline20$2,587
Silodosin18$2,221

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$152$124,650138 claims
Astellas Pharma US IncMyrbetriq$359$92,271136 claims
Antares Pharma, Inc.Xyosted$440$70,61692 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 400 urology providers in Michigan.

Other urology in Royal Oak

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →